The relationship between maintenance dosages of three vitamin K antagonists: Acenocoumarol, warfarin and phenprocoumon

Thrombosis Research

Volumn 123, Issue 2, 2008, Pages 225-230

  van Leeuwen, Yvonne ^a   Rosendaal, Frits R ^a   van der Meer, Felix J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulants; Clinical studies

Indexed keywords

ACENOCOUMAROL; PHENPROCOUMON; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; VEIN THROMBOSIS;

ACENOCOUMAROL; ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENPROCOUMON; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 55549105450     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.01.020     Document Type: Article

References (22)

1. Ginsberg J.S. Management of venous thromboembolism. N Engl J Med 335 (1996) 1816-1828
2. Hart R.G., Benavente O., McBride R., and Pierce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131 (1999) 492-501
3. Stein P.D., Alpert J.S., Bussey H.I., Dalen J.E., and Turpie A.G. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 119 (2001) 220S-227S
4. Hemker H.C., and Frank H.L. The mechanism of action of oral anticoagulants and its consequences for the practice of oral anticoagulation. Haemostasis 15 (1985) 263-270
5. Kelly J.G., and O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet 4 (1979) 1-15
6. O'Reilly R.A., Welling P.G., and Wagner J.G. Pharmacokinetics of warfarin following intravenous administration to man. Thromb Diath Haemorrh 25 (1971) 178-186
7. Thijssen H.H., Hamulyak K., and Willigers H. 4-hydroxycoumarin oral anticoagulants: pharmacokinetics-response relationship. Thromb Haemost 60 (1988) 35-38
8. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 44 (2005) 1227-1246
9. Tassies D., Freire C., Pijoan J., Maragall S., Monteagudo J., Ordinas A., et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 87 (2002) 1185-1191
10. Taube J., Halsall D., and Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96 (2000) 1816-1819
11. Barcellona D., Vannini M.L., Fenu L., Balestrieri C., and Marongiu F. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?. Thromb Haemost 80 (1998) 899-902
12. Breed W.P., van Hooff J.P., and Haanen C. A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon. Acta Med Scand 186 (1969) 283-288
13. Fekkes N., de Jonge H., Veltkamp J.J., Bieger R., and Loeliger E.A. Comparative study of the clinical effect of acenocoumarol (Sintrom) and phenprocoumon (Marcoumar) in myocardial infarction and angina pectoris. Acta Med Scand 190 (1971) 535-540
14. Fihn S.D., Gadisseur A.A., Pasterkamp E., van der Meer F.J.M., Breuking-Engbers W.G., Geven-Boere L.M., et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 90 (2003) 260-266
15. Gadisseur A.P., van der Meer F.J.M., Adriaansen H.J., Fihn S.D., and Rosendaal F.R. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 117 (2002) 940-946
16. Laporte S., Quenet S., Buchmuller-Cordier A., Reynaud J., Tardy-Poncet B., Thirion C., et al. Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost 89 (2003) 458-467
17. Pattacini C., Manotti C., Pini M., Quintavalla R., and Dettori A.G. A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol). Thromb Haemost 71 (1994) 188-191
18. Rodman T., Pastor H., and Resneck M.E. Phenprocoumon, diphenadione, warfarin and bishydroxycoumarin: a comparative study. Am J Med Sci 247 (1964) 655-660
19. Thijssen H.H., and Hemker H.C. [Oral anticoagulant treatment; which anticoagulant?]. Ned Tijdschr Geneeskd 128 (1984) 1559-1563
20. Kristiansen C., Lassen J.F., Dahler-Eriksen B.S., Dahler-Eriksen K., Larsen T.B., and Brandslund I. Evaluation of a simple dosage scheme for transition from phenprocoumon to warfarin in oral anticoagulation. Thromb Res 98 (2000) 157-163
21. Visser L.E., van Vliet M., van Schaik R.H., Kasbergen A.A., de Smet P., Vulto A.G., et al. The risk of overanticoagulation in patients with the cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14 1 (2004) 27-33
22. Schalekamp T., Brasse B.P., Roijers J.F., van Meegen E., van der Meer F.J.M., van Wijk E.M., et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 81 2 (2007) 185-193